Panacea Biotec Falls 6.30% Amid Mixed Technical Signals and Strong Sell Rating

29 December 2025: Heavy Trading Amid Strong Sell Rating

Panacea Biotec was among the most actively traded stocks by value on 29 Dec 2025, with a total traded value of ₹194.20 crores and volume exceeding 45 lakh shares. The stock opened at ₹415.95, a 2.16% gap up from the previous close, and reached an intraday high of ₹433.95, up 6.58% from the prior day’s close. Despite this strong intraday momentum, the stock settled at ₹422.85 early in the session before closing at ₹407.05, marking a 13.54% gain from the previous close of ₹358.50.

This surge occurred amid a strong sell Mojo Score of 9.0, reflecting institutional caution despite the price rally. The stock’s technical positioning showed it trading above short- and medium-term moving averages but still below the 200-day average, indicating resistance at longer-term levels. The spike in delivery volumes to 22.86 lakh shares on 26 Dec 2025, a massive 8,752.84% increase over the 5-day average, suggested significant investor conviction to hold shares amid volatile conditions.

30-31 December 2025: Consecutive Declines on Heavy Volume

Following the strong rally, Panacea Biotec’s stock price declined sharply over the next two trading days. On 30 Dec, the stock fell 2.26% to close at Rs.388.45 on volume of 1,48,411 shares, while the Sensex was nearly flat, down 0.01%. The downward trend intensified on 31 Dec, with the stock dropping 3.14% to Rs.376.25 despite the Sensex gaining 0.83% that day. The volume on 31 Dec was lower at 39,440 shares, indicating reduced liquidity but sustained selling pressure.

This pullback reflected the mixed technical momentum described in the week’s analysis, where moving averages remained mildly bearish and momentum oscillators such as RSI showed neutral readings. The stock’s inability to sustain the prior day’s gains suggested profit-taking and caution among investors amid the strong sell rating and sector headwinds.

1-2 January 2026: Modest Recovery Amid Positive Market Sentiment

Entering the new year, Panacea Biotec showed signs of stabilisation. On 1 Jan 2026, the stock gained 0.47% to close at Rs.378.00, with volume of 32,666 shares, while the Sensex rose 0.14%. The recovery continued on 2 Jan, with the stock advancing 0.90% to Rs.381.40 on very low volume of 8,534 shares, outperforming the Sensex’s 0.81% gain. These modest gains suggest some short-term buying interest, possibly from investors seeking to capitalise on the stock’s recent volatility and technical momentum shifts.

However, the low volumes on these days indicate cautious participation, consistent with the stock’s strong sell Mojo Score and the mixed technical signals. The weekly trend remains bearish overall, with the stock closing well below its opening price for the week and underperforming the benchmark index.

Daily Price Performance: Panacea Biotec vs Sensex

Key Takeaways

Positive Signals: The stock demonstrated strong intraday rallies on 29 Dec 2025, with a 13.54% gain signalling potential technical inflection. Delivery volumes surged dramatically prior to the week, indicating increased investor conviction. The modest recovery in early January suggests some short-term buying interest amid stabilising market conditions.

Cautionary Signals: Despite short-term rallies, Panacea Biotec closed the week down 6.30%, underperforming the Sensex’s 1.35% gain. The Mojo Score remains a strong sell at 9.0, reflecting ongoing fundamental and technical concerns. Moving averages and momentum oscillators present mixed to bearish signals, and volume declined sharply during the week’s sell-off and recovery phases, indicating cautious investor participation.

Sector and Market Context: Operating in the Pharmaceuticals & Biotechnology sector, Panacea Biotec faces regulatory and pricing pressures that contribute to volatility. Its small-cap status and market capitalisation of ₹2,493 crores add to the risk profile, with institutional investors likely balancing accumulation and trimming amid uncertain fundamentals.

Conclusion

Panacea Biotec’s week was characterised by heightened volatility, heavy trading volumes, and a significant price decline despite intermittent rallies. The stock’s strong sell Mojo Score and mixed technical indicators suggest that the recent momentum may not yet be sustainable. While delivery volumes and short-term price spikes indicate pockets of investor interest, the overall trend remains bearish with the stock underperforming the broader market. Investors should remain cautious and monitor volume trends and technical signals closely before considering new positions.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →